Human Osteoprotegerin/TNFRSF11B Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB805
Key Product Details
Validated by
Biological Validation
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Neutralization
Cited:
Immunohistochemistry, Neutralization, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 69146
Product Specifications
Immunogen
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human Osteoprotegerin/TNFRSF11B
Glu22-Leu401
Accession # AAB53709
Glu22-Leu401
Accession # AAB53709
Specificity
Detects human Osteoprotegerin/TNFRSF11B in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse Osteoprotegerin is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human Osteoprotegerin/TNFRSF11B Antibody
Osteoprotegerin/TNFRSF11B Inhibition of TRAIL/ TNFSF10-induced Cyto-toxicity and Neutral-ization by Human Osteoprotegerin/ TNFRSF11B Antibody.
In the presence of the metabolic inhibitor actinomycin D (0.5 µg/mL), Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera (Catalog # 805-OS) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/ TNFSF10 (50 ng/mL) activity elicited by Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human Osteoprotegerin/TNFRSF11B Monoclonal Antibody (Catalog # MAB805). The ND50 is typically 0.15-0.3 µg/mL.
Detection of Human Osteoprotegerin/TNFRSF11B by Western Blot
Methotrexate decreases mRNA and protein expression of RANKL and RANK in rheumatoid arthritis synovial-derived fibroblasts. A significant decrease in the receptor activator of the NF-kappa B ligand (RANKL) mRNA levels (A) with no changes in osteoprotegerin (OPG) mRNA levels (B) in the presence of methotrexate (MTX). Representative blots and graphs showing decrease of cellular RANKL protein expression (C and D) with no changes in the cellular OPG expression (C and E) in the presence of MTX. Decrease of soluble RANKL protein expression (F) with no changes in the soluble OPG expression (G) in the presence of MTX, where results are quantified by enzyme-linked immunosorbent assay. *p<0.05. Image collected and cropped by CiteAb from the following publication (https://arthritis-research.biomedcentral.com/articles/10.1186/ar4398), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Mouse Osteoprotegerin/TNFRSF11B by Western Blot
OPG exerts protective effects on cartilage catabolism.A. OPG/RANKL mRNA ratio in IL1-beta stimulated bone explants cultured with estradiol at 0.01 µM (E-8) and 1 µM (E-6), and with pamidronate (PAM). The graph represents the mRNA ratio to controls in 3 different experiments. B. Effect of OPG blockade by a neutralizing antibody (OPG-ab) on ARGS374 sequences expression in supernatants of cartilage explants cultured with conditioned bone media. Image of a representative Western blot, and the graph shows the mean quantifications ± SEM of 4 different experiments. Quantification was done on the 50 kDa bands. *: p<0.05. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0033543), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human Osteoprotegerin/TNFRSF11B Antibody
Application
Recommended Usage
Neutralization
Measured by its ability to neutralize Osteoprotegerin/TNFRSF11B-mediated inhibition of cytotoxicity in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND50) is typically 0.15-0.3 µg/mL in the presence of 0.1 µg/mL Recombinant Human Osteoprotegerin/TNFRSF11B Fc Chimera, 50 ng/mL Recombinant Human TRAIL/TNFSF10, and 0.5 µg/mL actinomycin D.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Reviewed Applications
Read 1 review rated 4 using MAB805 in the following applications:
Formulation, Preparation, and Storage
Purification
Protein A or G purified from ascites
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Osteoprotegerin/TNFRSF11B
Osteoprotegerin is a member of the TNF receptor superfamily expressed by many cell types. It exists in soluble monomeric and dimeric forms as a decoy receptor for its ligands, TRANCE and TRAIL. Osteoprotegerin functions as an antagonist to RANKL-induced osteoclastogenesis and bone resorption.
Alternate Names
OCIF, TNFRSF11B
Gene Symbol
TNFRSF11B
UniProt
Additional Osteoprotegerin/TNFRSF11B Products
Product Documents for Human Osteoprotegerin/TNFRSF11B Antibody
Product Specific Notices for Human Osteoprotegerin/TNFRSF11B Antibody
For research use only
Loading...
Loading...
Loading...